<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603042</url>
  </required_header>
  <id_info>
    <org_study_id>BHP 06-2018</org_study_id>
    <nct_id>NCT02603042</nct_id>
  </id_info>
  <brief_title>Biomarker for Hypophosphatasia Disease (BioHypophos)</brief_title>
  <acronym>BioHypophos</acronym>
  <official_title>Biomarker for Hypophosphatasia Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of a new MS-based biomarker for the early and sensitive diagnosis of&#xD;
      Hypophosphatasia disease from plasma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypophosphatasia (HPP) is a rare genetic disorder characterized the abnormal development of&#xD;
      bones and teeth. These abnormalities occur due to defective mineralization, the process by&#xD;
      which bones and teeth take up minerals such as calcium and phosphorus. These minerals are&#xD;
      required for proper hardness and strength. Defective mineralization results in bones that are&#xD;
      soft and prone to fracture and deformity. Defective mineralization of teeth can lead to&#xD;
      premature tooth loss. The specific symptoms can vary greatly from one person to another,&#xD;
      sometimes even among members of the same family. There are five major clinical forms of HPP&#xD;
      that range from an extremely severe form that can cause stillbirth to a form associated with&#xD;
      only premature loss of baby (deciduous) teeth, but no bone abnormalities. Hypophosphatasia is&#xD;
      caused by mutations in the tissue non-specific alkaline phosphatase (ALPL) gene. This gene is&#xD;
      also known as the TNSALP gene. Such mutations lead to low levels of the tissue nonspecific&#xD;
      alkaline phosphatase enzyme. Depending on the specific form, hypophosphatasia can be&#xD;
      inherited in an autosomal recessive or autosomal dominant manner.&#xD;
&#xD;
      Hypophosphatasia is an extremely variable disorder. Five major clinical forms have been&#xD;
      identified based primarily upon the age of onset of symptoms and diagnosis. These are known&#xD;
      as perinatal, infantile, childhood, adult, and odontohypophosphatasia. Generally, the&#xD;
      severity of these different forms of hypophosphatasia correlates to the residual alkaline&#xD;
      phosphate activity in the body, with less enzyme activity causing more severe dis- ease.&#xD;
      Because hypophosphatasia is a highly variable disorder, it is important to note that affected&#xD;
      individuals may not have all of the symptoms and that every individual case is unique. Some&#xD;
      children will develop severe complications early in life; others have mild disease that may&#xD;
      improve during young adult life.&#xD;
&#xD;
      Perinatal hypophosphatasia is associated with profound inactivity of alkaline phosphatase and&#xD;
      markedly impaired mineralization. Consequently, the skeleton fails to form properly in the&#xD;
      womb. Specific skeletal malformations may vary, but short, bowed arms and legs and&#xD;
      underdeveloped ribs often occur. Some pregnancies end in stillbirth. In other cases, affected&#xD;
      newborns survive for several days, but pass away from respiratory failure due to deformities&#xD;
      of the chest and underdeveloped lungs.&#xD;
&#xD;
      Infantile hypophosphatasia may have no noticeable abnormalities at birth, but symptoms may&#xD;
      become apparent at any time within the first six months. The initial symptom may be the&#xD;
      failure to gain weight and grow at the expected rate for age and gender referred to as&#xD;
      &quot;failure to thrive.&quot; Some affected babies later exhibit early fusion of the bones of the&#xD;
      skull (craniosynostosis), which can result in the head appearing disproportionately wide&#xD;
      (brachycephaly). Craniosynostosis may be associated with increased pressure of the&#xD;
      cerebrospinal fluid, a condition known as &quot;intracranial hypertension.&quot; This complication can&#xD;
      cause headaches, swelling of the optic disk (papilledema), and bulging of the eyes&#xD;
      (proptosis). Affected infants have softened, weakened bones that lead to the skeletal&#xD;
      malformations of rickets. Rickets is a bone disease that occurs during growth with softening&#xD;
      of bone and characteristic bowing deformities of the legs from growth plate abnormalities.&#xD;
      Enlarged wrist and ankle joints may occur. Affected infants may also have deformities in the&#xD;
      chest and ribs and rib fractures, predisposing them to pneumonia. Varying degrees of&#xD;
      pulmonary insufficiency and breathing difficulties may develop, potentially progressing to&#xD;
      life-threatening respiratory failure. Episodes of fever and bone pain, or tender bones may&#xD;
      occur. Some infants exhibit diminished muscle tone (hypotonia) so that a baby appears&#xD;
      &quot;floppy&quot; as well as elevated levels of calcium in the blood (hypercalcemia). Hypercalcemia&#xD;
      can cause vomiting, constipation, weakness, and poor feeding. In rare cases, vitamin&#xD;
      B6-dependent seizures may occur. Increased excretion of calcium may lead to kidney (renal)&#xD;
      damage. Sometimes there is spontaneous improvement in mineralization during early childhood,&#xD;
      with the exception of craniosynostosis. Short stature and skeletal deformities may persist&#xD;
      lifelong.&#xD;
&#xD;
      Childhood hypophosphatasia is highly variable, but is less severe than the infantile form.&#xD;
      Affected children may sometimes have craniosynostosis and exhibit signs of intra- cranial&#xD;
      hypertension. Skeletal malformations that resemble rickets may become apparent at 2 to 3&#xD;
      years of age. Bone and joint pain and fractures may occur. Baby teeth may fall out earlier&#xD;
      than normal. Some children are weak and experience delays in walking, and when they do learn&#xD;
      to walk may have a distinct, waddling gait. Spontaneous remission of bone symptoms has been&#xD;
      reported in young adult life, but such symptoms can recur during middle age or late&#xD;
      adulthood.&#xD;
&#xD;
      Adult hypophosphatasia is characterized by a wide variety of symptoms. Affected individuals&#xD;
      have osteomalacia, a softening of the bones in adults. Some individuals have a history of&#xD;
      rickets during childhood, or have experienced premature loss of their baby teeth. Individuals&#xD;
      with adult hypophosphatasia can experience fractures, especially stress fractures in the feet&#xD;
      or pseudofractures of the thigh. Repeated fractures can result in chronic pain and debility.&#xD;
      Fractures of the spine seem less common, but also occur. Bone pain is a common complication.&#xD;
      Some affected adults develop joint inflammation and pain near or around certain joints due to&#xD;
      the accumulation of calcium crystals (calcific periarthritis) or a condition called&#xD;
      chondrocalcinosis, characterized by the accumulation of calcium crystals within the cartilage&#xD;
      of joints, sometimes damaging the joint. Others have sudden, severe pain in the joint (pseudo&#xD;
      gout). Affected adults may experience loss of adult teeth.&#xD;
&#xD;
      Odontohypophosphatasia is characterized by the premature loss of teeth in childhood, or loss&#xD;
      of teeth in adulthood. It is an isolated finding that does not occur along with the&#xD;
      characteristic bone symptoms of other forms of hypophosphatasia.&#xD;
&#xD;
      For hypophosphatasia, mutations in the ALPL gene can be inherited in an autosomal recessive&#xD;
      or autosomal dominant manner. The perinatal and infantile forms of HPP are inherited in an&#xD;
      autosomal recessive manner. The childhood form can be autosomal recessive or autosomal&#xD;
      dominant. The adult form and odontohypophosphatasia typically are autosomal dominant&#xD;
      disorders, but in rare cases can be inherited as an autosomal recessive trait.&#xD;
&#xD;
      A diagnosis of hypophosphatasia is based upon identification of characteristic signs and&#xD;
      symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of&#xD;
      laboratory tests including x-ray studies. Proper diagnosis of hypophosphatasia is easy for&#xD;
      physicians who are familiar or experienced with this disorder.&#xD;
&#xD;
      New methods, like mass-spectrometry give a good chance to characterize specific metabolic&#xD;
      alterations in the blood (plasma) of affected patients that allow diagnosing in the future&#xD;
      the disease earlier, with a higher sensitivity and specificity.&#xD;
&#xD;
      Therefore it is the goal of the study to identify and validate a new biochemical marker from&#xD;
      the plasma of the affected patients helping to benefit other patients by an early diagnose&#xD;
      and thereby with an earlier treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sequencing of the Hypophosphatasia disease related gene</measure>
    <time_frame>4 weeks</time_frame>
    <description>Next-Generation Sequencing (NGS) of the ALPL gene will be performed. The mutation will be confirmed by Sanger sequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Hypophosphatasia disease specific biomarker candidates finding</measure>
    <time_frame>24 months</time_frame>
    <description>The quantitative determination of small molecules (molecular weight 150-700 kD, given as ng/Î¼l) within a dried blood spot sample will be validated via liquid chromatography multiple reaction-monitoring mass spectrometry (LC/MRM-MS) and compared with a merged control cohort. The statistically best validated molecule will be considered as a disease specific biomarker.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Defective Mineralization</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml&#xD;
      EDTA blood and a dry blood spot filter card are taken. To proof the correct di- agnosis of&#xD;
      Hypophosphatasia in those patients where up to the enrollment in the study no genetic testing&#xD;
      has been done, sequencing of Hypophosphatasia disease will be done. The analyses will be done&#xD;
      at the: Centogene AG Am Strande 7 18055 Rostock Germany&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        IInclusion Criteria:&#xD;
&#xD;
          -  Informed consent will be obtained from the patient or the parents before any study&#xD;
             related procedures.&#xD;
&#xD;
          -  Patients of both genders older than 2 month&#xD;
&#xD;
          -  The patient has a diagnosis of Hypophosphatasia disease or a high-grade suspicion for&#xD;
             Hypophosphatasia disease&#xD;
&#xD;
          -  High-grade suspicion present, if one or more inclusion criteria are valid:&#xD;
&#xD;
               -  Positive family anamnesis for Hypophosphatasia disease&#xD;
&#xD;
               -  Frequent fractures&#xD;
&#xD;
               -  Bone pain&#xD;
&#xD;
               -  Tooth loss&#xD;
&#xD;
               -  Osteopenia/Osteoporosis&#xD;
&#xD;
               -  Craniosynostosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No Informed consent from the patient or the parents before any study related&#xD;
             procedures.&#xD;
&#xD;
          -  Patients of both gender younger than 2 month&#xD;
&#xD;
          -  No diagnosis of Hypophosphatasia disease or no valid criteria for profound suspicion&#xD;
             of Hypophosphatasia disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centogene AG</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIRMAN Navi Mumbai Institute of Research In Mental And Neurological Handicap/Pediatric Geneticist</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo 8</city>
        <zip>00800c</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>India</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
  </removed_countries>
  <link>
    <url>http://centogene.com</url>
    <description>Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypophosphatasia Disease</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

